GSK plc today announced that AREXVY™, an approved Respiratory Syncytial Virus (RSV) vaccine, is now available at major retail pharmacies in the U.S.
AREXVY is currently indicated for preventing RSV-lower respiratory tract disease in individuals 60 years and older. An estimated 76.5 million people aged 60 and older in the U.S. may benefit from this RSV vaccine.
RSV is a seasonal disease, and an outbreak was recently in Florida
Read More
